CN118119707A - 抑制剂增加CRISPR/Cas插入效率的用途 - Google Patents

抑制剂增加CRISPR/Cas插入效率的用途 Download PDF

Info

Publication number
CN118119707A
CN118119707A CN202280066004.2A CN202280066004A CN118119707A CN 118119707 A CN118119707 A CN 118119707A CN 202280066004 A CN202280066004 A CN 202280066004A CN 118119707 A CN118119707 A CN 118119707A
Authority
CN
China
Prior art keywords
polynucleotide
inhibitor
cas
composition
pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280066004.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·马雷斯卡
S·斯维科维奇
N·阿克拉普
S·温伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN118119707A publication Critical patent/CN118119707A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280066004.2A 2021-09-30 2022-09-29 抑制剂增加CRISPR/Cas插入效率的用途 Pending CN118119707A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163250945P 2021-09-30 2021-09-30
US63/250945 2021-09-30
PCT/EP2022/077122 WO2023052508A2 (fr) 2021-09-30 2022-09-29 Utilisation d'inhibiteurs pour augmenter l'efficacité d'insertions de crispr/cas

Publications (1)

Publication Number Publication Date
CN118119707A true CN118119707A (zh) 2024-05-31

Family

ID=84330196

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280066004.2A Pending CN118119707A (zh) 2021-09-30 2022-09-29 抑制剂增加CRISPR/Cas插入效率的用途

Country Status (2)

Country Link
CN (1) CN118119707A (fr)
WO (1) WO2023052508A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024112944A1 (fr) * 2022-11-23 2024-05-30 Csl Behring L.L.C. Procédés d'amélioration d'efficacité d'édition

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5895309A (en) 1998-02-09 1999-04-20 Spector; Donald Collapsible hula-hoop
JP2008078613A (ja) 2006-08-24 2008-04-03 Rohm Co Ltd 窒化物半導体の製造方法及び窒化物半導体素子
CN104910025B (zh) 2008-11-07 2019-07-16 麻省理工学院 氨基醇类脂质和其用途
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
EP2609135A4 (fr) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(bêta-amino-alcools), leur préparation et utilisations de ceux-ci
WO2012135025A2 (fr) 2011-03-28 2012-10-04 Massachusetts Institute Of Technology Lipomères conjugués et utilisations associées
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
PT2800811T (pt) 2012-05-25 2017-08-17 Univ California Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição
EP3494997B1 (fr) 2012-07-25 2019-09-18 The Broad Institute, Inc. Protéines de liaison à l'adn inductibles, outils de perturbation du génome et leurs applications
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
SG10201912327SA (en) 2012-12-12 2020-02-27 Broad Inst Inc Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
EP3553174A1 (fr) 2012-12-17 2019-10-16 President and Fellows of Harvard College Ingénierie de génome humain guidée par arn
WO2014118272A1 (fr) 2013-01-30 2014-08-07 Santaris Pharma A/S Conjugués glucidiques d'oligonucléotides antimir-22
CN110540991B (zh) 2013-03-15 2023-10-24 通用医疗公司 使用截短的引导RNA(tru-gRNA)提高RNA引导的基因组编辑的特异性
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
EP3778899A1 (fr) 2013-05-22 2021-02-17 Northwestern University Clivage de l'adn orienté vers arn et édition génétique par l'enzyme cas9 provenant de neisseria meningitidis
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
ES2955957T3 (es) 2015-01-28 2023-12-11 Caribou Biosciences Inc Polinucleótidos de ADN/ARN híbridos CRISPR y procedimientos de uso
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2019099943A1 (fr) 2017-11-16 2019-05-23 Astrazeneca Ab Compositions et méthodes pour améliorer l'efficacité de stratégies knock-in basées sur cas9
GB201813060D0 (en) 2018-08-10 2018-09-26 Artios Pharma Ltd Novel compounds
CA3141827A1 (fr) 2019-05-30 2020-12-03 Magna International Inc. Systeme et procede d'optimisation d'entrainement de moteur
JP7401651B2 (ja) 2019-08-09 2023-12-19 アルティオス ファーマ リミテッド がんの治療における使用のためのヘテロ環式化合物
US11530425B2 (en) * 2019-10-09 2022-12-20 Massachusetts Institute Of Technology Systems, methods, and compositions for correction of frameshift mutations
EP4058467A1 (fr) * 2019-12-24 2022-09-21 Selexis SA Intégration ciblée dans des séquences de mammifère pour améliorer l'expression génique

Also Published As

Publication number Publication date
WO2023052508A3 (fr) 2023-05-11
WO2023052508A2 (fr) 2023-04-06

Similar Documents

Publication Publication Date Title
US11555181B2 (en) Engineered cascade components and cascade complexes
US20200239863A1 (en) Tracking and Manipulating Cellular RNA via Nuclear Delivery of CRISPR/CAS9
CN108350489B (zh) 用于使用rna引导的核酸结合蛋白的分子邻位检测的方法和试剂
EP3080256B1 (fr) Plateforme nucléase cas9 pour ingénierie génomique de micro-algues
DK3155099T3 (en) NUCLEASE MEDIATED DNA COLLECTION
KR102494449B1 (ko) 진핵 게놈 변형을 위한 조작된 cas9 시스템
AU2018273968A1 (en) Using split deaminases to limit unwanted off-target base editor deamination
US20230340538A1 (en) Compositions and methods for improved site-specific modification
US20200017852A1 (en) Compositions and methods for target nucleic acid modification
US20210198642A1 (en) Compositions and methods for improved nucleases
US20230287377A1 (en) Crispr/cas fusion proteins and systems
CN118119707A (zh) 抑制剂增加CRISPR/Cas插入效率的用途
US20230116223A1 (en) Nuclease-scaffold composition delivery platform
US20240182890A1 (en) Compositions and methods for site-specific modification
CN117377761A (zh) 用于位点特异性修饰的组合物和方法
EP4323514A1 (fr) Jonction d'extrémité médiée par une homologie non virale

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication